Merck & Co., Inc. (NYSE:MRK) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Analyst consensus: Nineteen brokerages rate Merck a "Moderate Buy" (11 buys, 7 holds, 1 strong buy) with an average 1‑year price target of $128.47.
• Regulatory/clinical catalysts: The FDA granted Priority Review for ifinatamab deruxtecan and Merck received expanded EU approval for KEYTRUDA regimens plus strong Phase 3 results for enlicitide decanoate, which could meaningfully expand its oncology and LDL‑lowering franchises.
• Financials and near‑term caution: Merck beat the quarter (EPS $2.04 vs. $2.01; revenue $16.4B), set FY2026 EPS guidance of $5.00–5.15 and pays a $0.85 quarterly dividend (≈2.8% yield), but recent insider sales and a ~1% stock dip signal some near‑term investor caution.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) has received an average rating of "Moderate Buy" from the nineteen analysts that are currently covering the company, Marketbeat reports. Seven analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $128.4706.

A number of equities research analysts have commented on MRK shares. Zacks Research upgraded Merck & Co., Inc. from a "strong sell" rating to a "hold" rating in a report on Tuesday, March 17th. Deutsche Bank Aktiengesellschaft upgraded Merck & Co., Inc. from a "hold" rating to a "buy" rating and set a $150.00 target price on the stock in a report on Friday, February 13th. TD Cowen increased their target price on Merck & Co., Inc. from $100.00 to $120.00 and gave the company a "hold" rating in a report on Tuesday, January 20th. Weiss Ratings reiterated a "hold (c)" rating on shares of Merck & Co., Inc. in a report on Monday, December 29th. Finally, Cantor Fitzgerald increased their target price on Merck & Co., Inc. from $116.00 to $120.00 and gave the company a "neutral" rating in a report on Wednesday, February 4th.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: UBS raised its price target on MRK to $145 and kept a Buy rating, increasing upside expectations and providing an analyst-led bullish signal. Benzinga
• Positive Sentiment: The FDA accepted and granted Priority Review to the BLA for ifinatamab deruxtecan (co-developed with Daiichi Sankyo) for previously treated extensive-stage small cell lung cancer — this could meaningfully expand Merck’s oncology franchise if approved. Ifinatamab Deruxtecan Granted Priority Review
• Positive Sentiment: Merck received expanded EU approval for KEYTRUDA‑based regimens in platinum‑resistant ovarian cancer and announced strong Phase 3 results for enlicitide decanoate (LDL lowering) with a near‑term FDA priority review filing planned — both support revenue diversification beyond existing indications. Merck Extends KEYTRUDA Reach
• Neutral Sentiment: “Big Pharma is thinking small” commentary notes industry M&A and deal discipline trends; smaller, targeted deals can help biotech partners and reduce mega‑deal risk for large pharma — a mixed structural factor for Merck’s M&A outlook. Big Pharma Is Thinking Small on Deals
• Neutral Sentiment: Sector headlines — including Eli Lilly’s strong run and other biotech successes — are drawing investor attention; competition and valuation rotations in healthcare can shift relative flows away from Merck in the near term. How Eli Lilly Stock Rises To $2,000
• Neutral Sentiment: Other sector moves (e.g., a biotech’s successful pancreatic cancer Phase 3 and Organon M&A rumors) are driving healthcare volatility but aren’t directly tied to Merck fundamentals. This Biotech Stock Soars 39%
• Negative Sentiment: A market write-up highlighted MRK “sinking” while broader markets gained, signaling investor profit‑taking or short‑term rotation out of the stock. This captures today’s downward price move and sentiment pressure. Merck (MRK) Stock Sinks As Market Gains
• Negative Sentiment: Morgan Stanley issued a Hold on MRK (reported via press coverage), a more cautious stance that can limit near‑term upside by tempering investor enthusiasm despite the UBS upgrade. Merck Gets a Hold from Morgan Stanley

Merck & Co., Inc. Stock Down 1.0%

Merck & Co., Inc. stock opened at $120.19 on Tuesday. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.54 and a quick ratio of 1.30. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $125.14. The company has a market cap of $296.86 billion, a PE ratio of 16.51, a price-to-earnings-growth ratio of 2.44 and a beta of 0.26. The stock's 50 day moving average price is $119.19 and its 200 day moving average price is $105.13.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The company had revenue of $16.40 billion during the quarter, compared to the consensus estimate of $16.19 billion. During the same period last year, the firm earned $1.72 EPS. The company's revenue for the quarter was up 5.0% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, sell-side analysts predict that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th were paid a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend was Monday, March 16th. Merck & Co., Inc.'s payout ratio is presently 46.70%.

Insider Transactions at Merck & Co., Inc.

In other news, insider Johannes Jacobus Oosthuizen sold 15,000 shares of the business's stock in a transaction on Friday, February 6th. The shares were sold at an average price of $121.87, for a total transaction of $1,828,050.00. Following the completion of the sale, the insider directly owned 21,197 shares of the company's stock, valued at $2,583,278.39. The trade was a 41.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Richard R. Deluca sold 37,685 shares of the business's stock in a transaction on Friday, February 6th. The shares were sold at an average price of $120.92, for a total transaction of $4,556,870.20. Following the sale, the executive vice president directly owned 160,174 shares of the company's stock, valued at $19,368,240.08. This represents a 19.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 320,176 shares of company stock worth $38,281,735 in the last three months. 0.13% of the stock is currently owned by company insiders.

Institutional Trading of Merck & Co., Inc.

A number of institutional investors have recently added to or reduced their stakes in MRK. Brighton Jones LLC grew its position in shares of Merck & Co., Inc. by 29.5% during the 4th quarter. Brighton Jones LLC now owns 38,278 shares of the company's stock valued at $3,808,000 after buying an additional 8,710 shares during the last quarter. Sivia Capital Partners LLC grew its position in shares of Merck & Co., Inc. by 52.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company's stock valued at $910,000 after buying an additional 3,941 shares during the last quarter. Diversify Advisory Services LLC grew its position in shares of Merck & Co., Inc. by 94.1% during the 2nd quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company's stock valued at $2,590,000 after buying an additional 15,636 shares during the last quarter. Diversify Wealth Management LLC grew its position in shares of Merck & Co., Inc. by 22.2% during the 2nd quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company's stock valued at $3,054,000 after buying an additional 6,897 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Merck & Co., Inc. by 111.7% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company's stock valued at $53,918,000 after purchasing an additional 359,356 shares during the period. 76.07% of the stock is owned by hedge funds and other institutional investors.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.